Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES Trial
ARCHES: OS by high or low disease volume and progression to mHSPC or de novo mHSPCПодробнее
ARCHES trial: androgen deprivation therapy with enzalutamide or placebo in mHSPCПодробнее
Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-...Подробнее
New Approaches to Metastatic Hormone Sensitive Prostate CancerПодробнее
ARCHES trialПодробнее
ARCHES: enzalutamide plus ADT in mHSPC subgroupsПодробнее
ARCHES trial overview: ADT plus enzalutamide for metastatic hormone-sensitive prostate cancerПодробнее
ARCHES trial: enzalutamide plus ADT for mHSPCПодробнее
Update on the ARCHES Trial: New Indication for Enzalutamide in mHSPCПодробнее
ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamideПодробнее
Update on overall survival in ARCHES trialПодробнее
STREAM trial: enzalutamide and androgen deprivation therapy with salvage radiation in men with h...Подробнее
ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spreadПодробнее
Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPCПодробнее
Update on ARCHES trial: implications for prostate cancer treatmentПодробнее
ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPCПодробнее
Enzalutamide as treatment for men with mHSPC who have received testosterone suppressionПодробнее
Final OS analysis from ARCHESПодробнее
ARCHES: radiographic progression in the absence of PSA progression in patients with mHSPCПодробнее
Updated overall survival outcomes in ENZAMET (ANZUP 1304)Подробнее